HOME / INVESTORS / BOARD OF DIRECTORS AND CEO

Kurt Nilsson
Chairman of the board.
Member of the board since 1996.
Born 1953. Founder of Glycorex Transplantation AB and R&D Manager. Doctor of Engineering in chemistry and applied biochemistry at Lund University. Senior lecturer in biotechnology.
Shareholding including related parties: 3,268,000 A restricted shares and 3,979,051 B unrestricted shares. 

Christer Ahlberg
Member of the board since 2020.
Born 1971.
Christer holds a BSc in business administration and economics from Örebro University. President and Chief Executive Officer of Sedana Medical since February 2017. Former experience in the pharmaceutical industry includes CEO at Unimedic Group (2010–2016), CEO at Eisai AB (2005–2010) and more than 10 years of experience in leading positions in sales and marketing at e.g. AstraZeneca, Meda and Wyeth.
Other current engagements: Board member in FrostPharma AB and Prooxpharma AB. CEO and deputy board member in Waxholm by the sea aktiebolag.
Shareholding: 45,000 B unrestricted shares.

Claes Blanche
Member of the board since 2018 (member of the board during 2000 – 2008).
Born 1957.
Master of Engineering at KTH (Royal Institute of Technology) and business degree from Stockholm School of Economics. More than 30 years of experience in management, sales and marketing. COO Biacore, Nordic CEO Guidant/Boston Scientific, Nordic CEO Sorin Group, president Boule Medical AB, CEO Blanche Science Advisors (ongoing).
Shareholding including related parties: 84,316 B unrestricted shares.

Kerstin Jakobsson
Member of the board since 2015.
Born 1956.
Master of Engineering. 30 years of experience of research and development, marketing and sales in the medical technology industry, as well as corporate governance and business development in several international Swedish companies, such as Perstorp, Tecator, FOSS, HemoCue and SpectraCure. CEO at Medicon Village Innovation AB.
Shareholding: None

Tomas Westergren
Deputy member of the board since 2012.
Born 1964.
Master of Engineering, physician and doctor of philosophy in biochemistry, experience of research and clinical work with patients.
Shareholding: 1,560,000 B unrestricted shares

Pontus Nobréus
CEO since October 15, 2020.
Born 1964.
Master of Science from The Faculty of Engineering at Lund University and an MBA
from Henley Business School. More than 15 years of experience in leading commercial positions in the diagnostics and laboratory business including assignments in the US and South Africa. Experience from global business development, establishment of sales and distribution channels, as well as commercialization and market strategy from HemoCue, Svar Life Science and Biovica International.
Shareholding: 13,000 B unrestricted shares